Eliem Therapeutics Inc
NASDAQ:ELYM
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Mastercard Inc
NYSE:MA
|
Technology
|
|
US |
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Realty Income Corp
NYSE:O
|
Real Estate
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
2.45
10.2
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Berkshire Hathaway Inc
NYSE:BRK.A
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Mastercard Inc
NYSE:MA
|
US | |
Abbvie Inc
NYSE:ABBV
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Realty Income Corp
NYSE:O
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one ELYM stock under the Base Case scenario is hidden USD. Compared to the current market price of 8.28 USD, Eliem Therapeutics Inc is hidden .
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Eliem Therapeutics Inc
Run backtest to discover the historical profit from buying and selling ELYM based on its intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Sign up to unlock intrinsic valuation and risk & rewards analysis.
Price Target |
Loading
|
Revenue Forecast |
|
Operating Income Forecast |
|
Earnings Forecast |
|
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Eliem Therapeutics Inc
Balance Sheet Decomposition
Eliem Therapeutics Inc
Current Assets | 226m |
Cash & Short-Term Investments | 223.1m |
Other Current Assets | 2.9m |
Non-Current Assets | 21k |
PP&E | 21k |
Current Liabilities | 3.7m |
Accounts Payable | 610k |
Accrued Liabilities | 3.1m |
Earnings Waterfall
Eliem Therapeutics Inc
Revenue
|
0
USD
|
Operating Expenses
|
-69.5m
USD
|
Operating Income
|
-69.5m
USD
|
Other Expenses
|
5.3m
USD
|
Net Income
|
-64.2m
USD
|
Free Cash Flow Analysis
Eliem Therapeutics Inc
USD | |
Free Cash Flow | USD |
ELYM Profitability Score
Profitability Due Diligence
Eliem Therapeutics Inc's profitability score is hidden . The higher the profitability score, the more profitable the company is.
Score
Eliem Therapeutics Inc's profitability score is hidden . The higher the profitability score, the more profitable the company is.
ELYM Solvency Score
Solvency Due Diligence
Eliem Therapeutics Inc's solvency score is hidden . The higher the solvency score, the more solvent the company is.
Score
Eliem Therapeutics Inc's solvency score is hidden . The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ELYM Price Targets Summary
Eliem Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for ELYM is 4.5 USD .
Shareholder Yield
Current shareholder yield for ELYM is hidden .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
ELYM Price
Eliem Therapeutics Inc
Average Annual Return | -50.56% |
Standard Deviation of Annual Returns | 26.94% |
Max Drawdown | -92% |
Market Capitalization | 553m USD |
Shares Outstanding | 66 790 000 |
Percentage of Shares Shorted | 1.54% |
Ownership
ELYM Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Eliem Therapeutics, Inc. operates as a clinical-stage biotechnology company. The company is headquartered in Redmond, Washington and currently employs 19 full-time employees. The company went IPO on 2021-08-10. The firm focuses on developing novel therapies for neuronal excitability disorders that addresses unmet needs in chronic pain, neuropsychiatry, epilepsy, and other disorders of the perishable and central nervous system. The firm offers two lead clinical-stage candidates: ETX-810 and ETX-155. ETX-810 is a palmitoylethanolamide (PEA) prodrug developed for the treatment of diabetic peripheral neuropathic pain (DPNP) and pain associated with lumbosacral radiculopathy (LSRP). ETX-810 is being evaluated in two Phase II a clinical trial. ETX-155 is a neurosteroid gamma-aminobutyric acid type A (GABAA) receptor positive allosteric modulator (PAM) developed for major depressive disorder (MDD), perimenopausal depression (PMD) and focal onset seizures (FOS). The firm provides two programs in addition to its clinical candidates, namely Kv7.2/3 program and anxiolytic.
Contact
IPO
Employees
Officers
The intrinsic value of one ELYM stock under the Base Case scenario is hidden USD.
Compared to the current market price of 8.28 USD, Eliem Therapeutics Inc is hidden .